Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=4d0c5b6b32708f0543d895c3b29a2277
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2022 Results and Reviews Operations
IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference


IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that

IMV Inc. Announces Chief Financial Officer to Retire: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. Announces Chief Financial Officer to Retire


IMV Inc. (NASDAQ: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that

IMV Inc. Announces Third Quarter 2021 Financial and Operational Update: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. Announces Third Quarter 2021 Financial and Operational Update


IMV Inc. (“IMV” or “the Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing immune-educating cancer therapies, based on its novel DPX platform, that target solid and blood

Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November

Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting : https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and blood cancers while preserving

IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating cancer therapies, based on its novel DPX platform, to treat solid and blood cancers while

Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today issued its financial results for the third quarter ended September 30, 2021. Amounts, unless specified otherwise, are

Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced updated

Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021, before the markets open

Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced that

Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that the

Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that a poster describing

IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that two abstracts

Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences : https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will present at the following upcoming virtual investor conferences:

Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will participate in the H.C. Wainwright & Co. 23rd Annual Global Investment

IMV Inc. to Present at Three Investor Conferences in September: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. to Present at Three Investor Conferences in September


IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that members of IMV’s

Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease

IMV Inc. Announces Second Quarter 2021 Financial and Operational Results: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. Announces Second Quarter 2021 Financial and Operational Results


IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational

IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced the final topline

Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the Virtual BTIG Annual Biotech

Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”) today issued its financial results for the second quarter ended June 30, 2021. Amounts, unless specified otherwise, are

IMV Announces CEO Transition: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Announces CEO Transition


IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that Frederic Ors has stepped

IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021


IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, announced

IMV to Participate in the BTIG Virtual Biotechnology Conference: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV to Participate in the BTIG Virtual Biotechnology Conference


IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today